Bilimsel Makale Arama | NeuralCipher AI

Açık erişim

PET imaging of noradrenaline transporters in Parkinson's disease: focus on scan time.

Brumberg J, Tran-Gia J, Lapa C, Isaias IU, Samnick S.

Ann Nucl Med · 2018-10-06

DOI: 10.1007/s12149-018-1305-5PMID: 30293197

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

PET imaging of [11C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding.

Varnäs K, Cselényi Z, Jucaite A, Halldin C, Svenningsson P, Farde L, Varrone A.

Eur J Nucl Med Mol Imaging · 2018-10-01

DOI: 10.1007/s00259-018-4161-6PMID: 30270409

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective.

Thobois S, Prange S, Scheiber C, Broussolle E.

Parkinsonism Relat Disord · 2018-08-30

DOI: 10.1016/j.parkreldis.2018.08.016PMID: 30181086

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Clinical characteristics of cognitive impairment in patients with Parkinson's disease and its related pattern in 18 F-FDG PET imaging.

Wu L, Liu FT, Ge JJ, Zhao J, Tang YL, Yu WB, Yu H, Anderson T, Zuo CT, Chen L, Wang J.

Hum Brain Mapp · 2018-07-12

DOI: 10.1002/hbm.24311PMID: 29999569

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia.

Walker Z, Gandolfo F, Orini S, Garibotto V, Agosta F, Arbizu J, Bouwman F, Drzezga A, Nestor P, Boccardi M, Altomare D, Festari C, Nobili F, EANM-EAN Task Force for the recommendation of FDG PET for Dementing Neurodegenerative Disorders.

Eur J Nucl Med Mol Imaging · 2018-05-19

DOI: 10.1007/s00259-018-4031-2PMID: 29779045

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Noradrenergic Dysfunction in Alzheimer's and Parkinson's Diseases-An Overview of Imaging Studies.

Peterson AC, Li CR.

Front Aging Neurosci · 2018-05-01

DOI: 10.3389/fnagi.2018.00127PMID: 29765316

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Development of a clinically feasible [11C]PE2I PET method for differential diagnosis of parkinsonism using reduced scan duration and automated reference region extraction.

Jonasson M, Appel L, Danfors T, Nyholm D, Askmark H, Frick A, Engman J, Furmark T, Sörensen J, Lubberink M.

Am J Nucl Med Mol Imaging · 2017-12-20

PMID: 29348981

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.

Pagano G, Yousaf T, Politis M.

Curr Neurol Neurosci Rep · 2017-10-03

DOI: 10.1007/s11910-017-0794-2PMID: 28975571

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Subthalamic nucleus stimulation effects on single and combined task performance in Parkinson's disease patients: a PET study.

Atkinson-Clement C, Maillet A, LeBars D, Lavenne F, Redouté J, Krainik A, Pollak P, Thobois S, Pinto S.

Brain Imaging Behav · 2017-08-01

DOI: 10.1007/s11682-016-9588-4PMID: 27704407

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Management Impact of Imaging Brain Vesicular Monoamine Transporter Type 2 in Clinically Uncertain Parkinsonian Syndrome with 18F-AV133 and PET.

Alexander PK, Lie Y, Jones G, Sivaratnam C, Bozinvski S, Mulligan RS, Young K, Villemagne VL, Rowe CC.

J Nucl Med · 2017-05-10

DOI: 10.2967/jnumed.116.189019PMID: 28490469

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease.

Koole M, Van Laere K, Ahmad R, Ceccarini J, Bormans G, Vandenberghe W.

Mov Disord · 2017-04-10

DOI: 10.1002/mds.27005PMID: 28394032

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.

Weng CC, Chen ZA, Chao KT, Ee TW, Lin KJ, Chan MH, Hsiao IT, Yen TC, Kung MP, Hsu CH, Wey SP.

PLoS One · 2017-03-03

DOI: 10.1371/journal.pone.0173503PMID: 28257461

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kayıtlar bilimsel kaynaklardan alınır. Bibliyografik kayıt sayısı, Türkçe çeviri veya editoryal onay sayısı değildir.

161 makale bulundu

PET imaging of noradrenaline transporters in Parkinson's disease: focus on scan time.

PET imaging of [<sup>11</sup>C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding.

What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective.

Clinical characteristics of cognitive impairment in patients with Parkinson's disease and its related pattern in <sup>18</sup> F-FDG PET imaging.

Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia.

Noradrenergic Dysfunction in Alzheimer's and Parkinson's Diseases-An Overview of Imaging Studies.

Development of a clinically feasible [<sup>11</sup>C]PE2I PET method for differential diagnosis of parkinsonism using reduced scan duration and automated reference region extraction.

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.

Subthalamic nucleus stimulation effects on single and combined task performance in Parkinson's disease patients: a PET study.

Management Impact of Imaging Brain Vesicular Monoamine Transporter Type 2 in Clinically Uncertain Parkinsonian Syndrome with <sup>18</sup>F-AV133 and PET.

Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease.

Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.

Filtreler